drugset / Trial / NCT00000227

Alternate-Day Buprenorphine Administration. Phase VIII - 9

NCT00000227

CrossoverTreatment

Summary

The purpose of this study is to evaluate open buprenorphine dosing with dose choice.

Timeline

Start
1994-08
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Buprenorphine Other / unclassified